ASSOCIATION OF SERUM ADENOSINE DEAMINASE LEVELS WITH ACUTE KIDNEY INJURY IN DIABETIC PATIENTS

M USMAN; F SHAH

doi:10.54112/bcsrj.v2024i1.1236

Authors

M USMAN Department of Medicine, KDA Hospital, Kohat, Pakistan
F SHAH Department of Medicine, KDA Hospital, Kohat, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1236

Keywords:

Diabetes , Acute kidney injury , serum adenosine deaminase , association

Abstract

Diabetes mellitus is a significant global health issue, and complications such as acute kidney injury (AKI) are prevalent in patients with type 2 diabetes. Serum adenosine deaminase (ADA) has been suggested as a potential biomarker for various metabolic conditions, including inflammation and kidney injury, but its association with diabetic kidney health remains understudied. Objective: To assess the association of serum adenosine deaminase (ADA) levels with acute kidney injury (AKI) in patients with type 2 diabetes. Methods: This observational comparative study was conducted at DHQ Teaching Hospital KDA, Kohat, from February 7, 2023, to August 7, 2023, following ethical approval. A total of 120 participants were enrolled, including 60 patients with type 2 diabetes and 60 non-diabetic controls. Laboratory investigations for both groups included serum ADA (U/L), HbA1c (%), and estimated glomerular filtration rate (eGFR) (mL/min/1.73 m²). Statistical comparisons between groups were made using appropriate tests, and correlations between serum ADA and other parameters were assessed. Results: The mean age of diabetic patients was 55.40 ± 8.29 years, and that of controls was 54.58 ± 21.64 years. The mean serum ADA level in diabetic patients was significantly higher at 43 ± 4.29 U/L compared to 16.32 ± 1.20 U/L in controls (p = 0.0001). Diabetic patients had a mean HbA1c of 8.30 ± 0.59%, significantly higher than that of controls (5.28 ± 0.59%) (p = 0.0001). The mean eGFR in diabetic patients was 82.61 ± 17.22 mL/min/1.73 m², lower than in controls (105.97 ± 12.07 mL/min/1.73 m²) (p = 0.0001). In diabetic patients, serum ADA levels were positively correlated with HbA1c (indicating poorer glycemic control) and negatively correlated with eGFR (suggesting declining kidney function). Conclusion: Elevated serum adenosine deaminase levels in type 2 diabetic patients are significantly associated with poor glycemic control and decreased kidney function. These findings indicate that serum ADA could serve as a potential biomarker for monitoring glycemic status and kidney health in diabetic patients at risk for acute kidney injury.

Downloads

Download data is not yet available.

References

Deshmukh CD, Jain A, Nahata B. Diabetes mellitus: a review. Int J Pure Appl Biosci. 2015;3(3):224-30.

Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nature reviews nephrology. 2020;16(7):377-90.

Lee PG, Halter JB. The pathophysiology of hyperglycemia in older adults: clinical considerations. Diabetes care. 2017;40(4):444-52.

Marcovecchio ML. Complications of acute and chronic hyperglycemia. US Endocrinol. 2017;13(1):17-21.

Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity. Biomedicine & pharmacotherapy. 2018;107:306-28.

Balaji R, Duraisamy R, Kumar M. Complications of diabetes mellitus: A review. Drug Invention Today. 2019;12(1).

Mohajan D, Mohajan HK. Hyperglycaemia among Diabetes Patients: A Preventive Approach. Innovation in Science and Technology. 2023;2(6):27-33.

Afroz A, Alam K, Hossain MN, Biswas A, Ali L, Magliano DJ, et al. Burden of macro-and micro-vascular complications of type 2 diabetes in Bangladesh. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(2):1615-22.

Yu SM-W, Bonventre JV. Acute kidney injury and progression of diabetic kidney disease. Advances in chronic kidney disease. 2018;25(2):166-80.

Patschan D, Müller G. Acute kidney injury in diabetes mellitus. International journal of nephrology. 2016;2016(1):6232909.

NATESAN SN. Serum adenosine deaminase levels in acute kidney injury. University Journal of Pre and Paraclinical Sciences. 2016;2(4).

Chielle EO, Rigon KA, Arcari IA, Stein V, Santos GAd. Influence of hemodialysis on the plasma concentration of adenosine deaminase in patients with chronic kidney disease. Jornal brasileiro de patologia e medicina laboratorial. 2015;51(3):153-7.

Lu C-f, Liu W-s, Ge X-q, Xu F. Serum adenosine deaminase levels are associated with diabetic kidney disease in type 2 diabetic patients. Endocrine Connections. 2021;10(9):973-9.

Shet SK. Study of Correlation of Serum Levels of Vitamin-D and Vascular Endothelial Growth Factor in Type 2 Diabetes Mellitus on Oral Hypoglycemic Drugs with 5 Years Duration: Rajiv Gandhi University of Health Sciences (India); 2017.

Stentz FB, Kitabchi AE. Activated T lymphocytes in type 2 diabetes: implications from in vitro studies. Current drug targets. 2003;4(6):493-503.

Hovi T, Smyth J, Allison A, Williams S. Role of adenosine deaminase in lymphocyte proliferation. Clinical and experimental immunology. 1976;23(3):395.

Chang F-Y, Shaio M-F. Decreased cell-mediated immunity in patients with non-insulin-dependent diabetes mellitus. Diabetes research and clinical practice. 1995;28(2):137-46.

Desrosiers MD, Cembrola KM, Fakir MJ, Stephens LA, Jama FM, Shameli A, et al. Adenosine deamination sustains dendritic cell activation in inflammation. The Journal of Immunology. 2007;179(3):1884-92.

Khemka VK, Bagchi D, Ghosh A, Sen O, Bir A, Chakrabarti S, et al. Raised serum adenosine deaminase level in nonobese type 2 diabetes mellitus. The Scientific World Journal. 2013;2013(1):404320.